Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Elranatamab · Elrexfio, RN-613

Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E) · developed by Pfizer

Approved FDA, Aug 2023
PFE Developer
1 Registered trials

What is Elranatamab?

Elranatamab is a bispecific BCMA-directed CD3 T-cell engaging antibody. It binds BCMA on plasma cells and multiple myeloma cells and CD3 on T-cells, leading to cytolysis of BCMA-expressing cells. It is studied in multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Elrexfio, RN-613
Drug type
Bispecific antibody
Targets
B-cell maturation antigen (TNFRSF17), CD3 (CD3E)
Mechanism
Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E)
Pathways
T-cell mediated cytolysis, proinflammatory cytokine release
Therapy area
Oncology
Developer
Pfizer Inc (PFE)
FDA status
Approved as Elrexfio (August 14, 2023), BLA761345 · FDA label
UNII
L0HR9A577V

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06152575 Phase 3 Multiple Myeloma Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Other drugs acting on TNFRSF17 / CD3E

More from Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Elranatamab

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.